Rating Change
Chardan Capital analysts reiterated a Buy rating on ProQR Therapeutics N.V. (NASDAQ:PRQR) on June 26, 2026.
reiterateNASDAQ:PRQR
Chardan Capital Reiterates Buy Rating on ProQR Therapeutics N.V. (PRQR)
Rating Change Chardan Capital analysts reiterated a Buy rating on ProQR Therapeutics N.V. (NASDAQ:PRQR) on June 26, 2026. Market Context ProQR Therapeutics N.V.
Market Context
ProQR Therapeutics N.V. operates in the Healthcare sector. The stock currently trades at $1.53 with a market capitalization of $249.7M.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ProQR Therapeutics N.V..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ProQR Therapeutics N.V.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 26, 2026 | Jones Trading | Buy | N/A |
| Jun 26, 2026 | Chardan Capital | Buy | N/A |
| Apr 09, 2026 | Chardan Capital | Buy | N/A |
| Nov 04, 2025 | Chardan Capital | Buy | N/A |
| Aug 08, 2025 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PRQR Stock Page
Frequently Asked Questions
What does a Buy rating mean for PRQR?
A Buy rating from Chardan Capital reflects the analyst's outlook on ProQR Therapeutics N.V. (NASDAQ:PRQR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PRQR forecast page.
